Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2022-08-16 Notice of Dividend Amou…
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Dividend/Distribution - CYC 4 pages 24.9KB
Notice of Dividend Amount Classification · 100% confidence The document is a notification of dividend/distribution for Cyclopharm Limited, detailing the dividend amount, ex-date, record date, and payment date. It is a formal announcement of dividend payment details rather than a full financial report or analysis. The document length is under 5,000 characters and it primarily serves to inform shareholders about dividend specifics. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2022-08-16 English
Half Yearly Report and Accounts 33 pages 1.5MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Cyclopharm Limited Appendix 4D - Half Year Report' and covers the half year ended 30 June 2022. It includes detailed financial data such as revenues, net loss, cash balances, and segment performance. The document contains comprehensive financial statements, management discussion, auditor's review report, and notes to the financial statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The Appendix 4D is a regulatory form used in Australia for half-year financial reporting, which aligns with the definition of an Interim / Quarterly Report (IR). The document is not merely an announcement or certification but contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2022
2022-08-16 English
Half Year 2022 Results 4 pages 280.2KB
Interim / Quarterly Report Classification · 95% confidence The document is an announcement dated 17 August 2022 from Cyclopharm Limited reporting the half year financial results for the six months ending 30 June 2022. It includes detailed financial data such as revenue figures, net loss, gross margin, cash reserves, dividend declaration, and operational updates including FDA approval status and strategic outlook. The content is comprehensive and covers financial performance, business developments, and outlook for the half year period, which aligns with the characteristics of an Interim / Quarterly Report (IR). The document is about 10,994 characters long, indicating it is a full report rather than a brief announcement or a certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2022
2022-08-16 English
Technegas Used In Multicenter COVID Study 2 pages 181.6KB
Regulatory Filings Classification · 95% confidence The document is an announcement from Cyclopharm Limited regarding an independent multicentre study about their product Technegas™ used in diagnosing pulmonary embolism in COVID-19 patients. It references a published study in a medical journal and highlights the clinical significance and market potential of the product. The document is structured as a press release or company announcement to the Australian Securities Exchange (ASX) and does not contain financial statements, detailed financial analysis, or regulatory certifications. It is not a full annual or interim report, audit report, earnings release, or any other detailed financial filing. It is also not a notice of voting results, board changes, or capital changes. The document is a regulatory announcement informing the market about clinical study results and their implications for the company’s business. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and company updates that do not fit other specific categories.
2022-07-06 English
1H 2022 Business Update - Record Revenues 4 pages 176.6KB
Management Reports Classification · 95% confidence The document is an announcement dated 4 July 2022 from Cyclopharm Limited providing a business update for the half year ended 30 June 2022. It includes unaudited preliminary financial performance highlights such as record revenues, growth percentages, cash position, and progress on USFDA approval. The document explicitly states that the company anticipates announcing further information about its half year performance in its 1H 2022 results announcement scheduled for late August 2022, indicating this is a preliminary update rather than a full interim or quarterly report. The document contains some financial data but is primarily a business update and outlook rather than a comprehensive financial report with full financial statements and analysis. It is not a full Annual Report (10-K), nor a detailed Interim/Quarterly Report (IR) because it lacks substantive financial statements and detailed analysis. It is also not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) since it contains substantive business and financial update content rather than just a notice or certification. The document fits best as a Capital/Financing Update (CAP) or a Management Report (MDA). However, since it focuses on financial performance highlights, revenue growth, cash position, and strategic progress (including FDA approval and growth strategy), it aligns most closely with a Management Reports (MDA) filing, which covers management's detailed explanation of financial results, business trends, and outlook. Confidence is high given the detailed financial and business commentary and the nature of the document as a business update with financial highlights but not a full financial report.
2022-07-03 English
Change of Director's Interest Notice 2 pages 206.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares held before and after the change, the nature of the transaction (on-market trade), and dates. There is no financial performance data, earnings information, or report content. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document length is 3273 characters, which is consistent with a detailed notice rather than a full report or announcement of a report. Therefore, the correct classification is DIRS (Director's Dealing).
2022-06-13 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.